Next-gen surgical robots Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how a new generation of surgical robots changes hospital operations over the next ten years. The change spans soft tissue systems from new entrants, ambulatory surgery robots, cardiac and specialty platforms, and the software and data that link them to the operating room, and it ends a long period in which one company dominated soft tissue robotic surgery.

The case begins with competition arriving at the same time. Medtronic received FDA clearance for the Hugo system for urologic procedures in December 2025, CMR Surgical received clearance for Versius in the same month, and Johnson & Johnson announced FDA de novo authorization for Ottava on 22 July 2026. Three large programmes reaching the United States market within eight months puts a limit on the pricing power of any single supplier.

The first proof is the new design. Ottava places four robotic arms on a standard-size surgical table and stows them beneath it, and J&J states that it occupies 30% to 50% less space than boom and cart mounted systems. The pivotal study met its endpoints, announced in May 2026, and the authorization covers procedures such as gastric bypass, gallbladder and appendix removal. Space and set-up time are real costs in an operating room, so designs that reduce them speak directly to hospital managers.

The second proof is the deal flow. On 19 October 2026 coverage reported that Stryker will invest about USD 400 million in preferred equity in CMR Surgical, with an option to buy the remaining equity and exclusive U.S. sales rights for Versius. A large orthopaedic and endoscopy company buying its way into soft tissue robotics shows that the market is now attractive to established medtech groups, not only to start-ups.

The third proof is the incumbent response. Intuitive received FDA clearance in January 2026 for nine new cardiac indications and forecast worldwide da Vinci procedure growth of 13% to 15% for 2026, down from about 18% the previous year. Growth is still strong while slowing, which suggests the market is large enough for challengers to win share without breaking the leader.

The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players and the adoption trajectory to 2036.

It is a focused 112-page decision brief for hospital executives, ambulatory surgery operators, medtech companies, investors and policy makers. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which procedures and care sites adopt new robots first, how pricing and service models shift, and who captures value as surgical robotics broadens.

A surgical robot places instruments in the patient through small incisions and lets the surgeon control them from a console, with a magnified three-dimensional view. Benefits include precision, reduced fatigue and less invasive surgery, which can shorten hospital stays. New systems seek to keep these benefits while changing size, cost and workflow.

Architecture is the first area of change. Older systems use a single large cart. Newer designs use modular arms mounted on separate carts, on the table or on the ceiling. Ottava arms stow beneath the table, and Versius is modular so that it can fit across specialties and care sites. Smaller footprints matter in hospitals with limited space and in ambulatory centres.

Software and data are the second area. Systems record video, instrument force and motion, and link to learning and analytics platforms such as the Polyphonic ecosystem from J&J. Intuitive adds video replay and force measurement. Over time, software can guide set-up, score technique and support remote proctoring.

Specialty platforms are the third area. Cardiac, endovascular, microsurgical and ophthalmic robots address procedures that general platforms do not serve well. Examples include systems from Microbot, Stereotaxis, MMI and ForSight Robotics, and cardiac programmes at Intuitive, SS Innovations and Capstan Medical.

The limits are cost, evidence and training. A system costs well over a million dollars before instruments, and per-procedure costs matter to hospitals. Clinical evidence of better outcomes is mixed across procedures. Surgeons need training, and each platform has its own learning curve. The decade turns on whether competition reduces cost per procedure and whether evidence supports wider use.

The next-gen surgical robots market, covering next-generation surgical robotic systems, instruments and accessories, software and services across soft tissue, orthopaedic, cardiac and specialty procedures, and excluding non-robotic laparoscopic equipment, imaging systems and rehabilitation robots, is valued at USD 18–24 billion in 2026 and is projected to reach USD 55–80 billion by 2036, at a CAGR of 11–12%.

The 2026 base rests on the installed base of soft tissue and orthopaedic systems and the recurring revenue from instruments and service. From that base, growth follows new platforms entering hospitals and ambulatory centres. Each new system adds placements in sites that were not served, and each placement adds instrument sales for years.

The forecast is sensitive to hospital capital budgets, reimbursement and the outcome of competition on price. Regionally, North America leads on installed base and new launches, Europe and Japan on adoption in public systems, and China and India on domestic suppliers and growing volumes.

The base case assumes steady hospital investment, gradual share gains for challengers and continued growth at the leader, giving the inflection around 2030. An accelerated case adds fast reimbursement for ambulatory use and strong outcome evidence, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes budget pressure, slow launches and mixed evidence, holding growth at the bottom of the range.

Growth drivers

• New entrants with FDA clearance or authorization for soft tissue procedures.
• Demand for less invasive surgery and shorter stays.
• Move of procedures to ambulatory surgery centres.
• Strategic investment by large medtech groups.

Enablers

• Compact and modular system designs.
• Software, video and force data for guidance and training.
• Per-procedure and subscription pricing models.
• Established sales networks of companies such as Stryker and Medtronic.

Restraints and barriers

• High capital and per-procedure cost.
• Mixed evidence of outcome gains in some procedures.
• Surgeon training and platform-specific learning curves.
• Reimbursement limits in some markets.

Five converging forces will determine how fast next-generation surgical robots scale.

(1) Competition and pricing. (2) Clinical evidence. (3) Care site shift. (4) Software and data. (5) Reimbursement and capital budgets. The brief assesses each force for direction, speed and confidence.

The key players operating in next-generation surgical robotics include Intuitive Surgical, Inc., Medtronic plc, Johnson & Johnson, Stryker Corporation, CMR Surgical Ltd, Zimmer Biomet Holdings, Inc., Smith & Nephew plc, Globus Medical, Inc., Karl Storz SE & Co. KG, Medicaroid Corporation, SS Innovations International, Inc., Moon Surgical SAS, Distalmotion SA, Procept BioRobotics Corporation, Capstan Medical, Inc., Corcym S.r.l., Microbot Medical Inc., Stereotaxis, Inc., MMI Medical Microinstruments S.p.A., ForSight Robotics Ltd., Neocis Inc., Monogram Technologies Inc., Brainlab AG, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., NVIDIA Corporation, Olympus Corporation, Boston Scientific Corporation, Abbott Laboratories, HCA Healthcare, Inc., Mayo Clinic, Cleveland Clinic, SCA Health, the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, the Society of American Gastrointestinal and Endoscopic Surgeons and the American College of Surgeons.

The brief profiles representative players in each archetype and assesses which are positioned to lead as new platforms reach hospitals.

The competitive landscape is forming around six archetypes. The incumbent platform leader. Large medtech challengers. Specialty and ambulatory robot developers. Orthopaedic and device groups entering robotics. Imaging, software and data providers. Hospitals, regulators and professional bodies. Competitive intensity is moderate in 2026 and is expected to rise as launches broaden through 2030.

Where value migrates.

In 2026 value sits in systems and instruments from the leader and in the first launches of challengers. By 2030 it moves to per-procedure and subscription revenue, ambulatory platforms and software that raises utilisation. By 2036 it settles in data and services, training and remote support, and in platforms with low cost per case. System prices fall as competition grows, while recurring revenue and data grow in importance.

The signals converge on competition and care site shift. Three large programmes now have U.S. authorization, established medtech groups are buying in, and the incumbent is extending into cardiac surgery. Each signal moves surgical robotics from one dominant platform to a market with choice.

Research and patent activity reflects where the chain is weakest: haptic feedback, set-up automation, instrument cost, remote operation and AI guidance. The brief therefore tracks four indicators: procedures per system, share of procedures in ambulatory sites, cost per procedure and number of competing platforms in U.S. hospitals.

Regionally, North America leads on installed base and new launches, Europe and Japan on adoption in public systems, and China and India on domestic suppliers and growing volumes. General surgery, urology, gynaecology, orthopaedics and cardiac surgery are the first demand pools in that order.